NCT04903509View on ClinicalTrials.gov

A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide

PHASE1CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

June 8, 2021

Primary Completion Date

August 26, 2022

Study Completion Date

August 26, 2022

Conditions
Healthy
Interventions
DRUG

BI 1820237

BI 1820237

DRUG

Placebo

Placebo

DRUG

Saxenda®

Saxenda®

DRUG

Paracetamol-ratiopharm®

Paracetamol-ratiopharm®

Trial Locations (1)

68167

CRS Clinical Research Services Mannheim GmbH, Mannheim

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04903509 - A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide | Biotech Hunter | Biotech Hunter